Key result
Upregulated serum LINC00240 correlates with NAFLD and lipid metabolism, modulating progression by targeting miR-133a-3p.
Why the study?
Long non-coding RNAs play pivotal roles in diverse diseases including non-alcoholic fatty liver disease, prompting investigation into LINC00240 expression and its potential as a biomarker.
Are serum LINC00240 and miR-133a-3p potential diagnostic biomarkers for NAFLD?
Observational
Are serum LINC00240 and miR-133a-3p potential diagnostic biomarkers for NAFLD?
LINC00240 and miR-133a-3p may serve as diagnostic biomarkers for NAFLD and modulate its progression through lipid metabolic regulation.
Answers are grounded in this paper and cite their sources.
May support LINC00240 as NAFLD biomarker; leaves open validation before clinical adoption.
BACKGROUND: Long non-coding RNAs (lncRNAs) play pivotal roles in diverse diseases, including non-alcoholic fatty liver disease (NAFLD). This study aimed to explore the expression of LINC00240 in NAFLD patients, elucidating its potential as a biomarker. METHODS: RT-qPCR was employed to measure the levels of LINC00240 and miR-133a-3p. ROC curve analysed diagnostic value, luciferase reporter assay verified their targeting relationship, and lipid metabolism markers were detected for correlation analysis. RESULTS: Serum LINC00240 was upregulated and miR-133a-3p was downregulated in NAFLD patients. LINC00240 was positively correlated with TC, TG, ALT, and HOMA-IR. Both LINC00240 and miR-133a-3p displayed diagnostic potential. LINC00240 directly targeted miR-133a-3p. Knockdown of LINC00240 reduced lipid metabolism parameters, while was partially reversed by miR-133a-3p antagomir. CONCLUSION: LINC00240 and miR-133a-3p are potential diagnostic biomarkers for NAFLD. LINC00240/miR-133a-3p axis modulates NAFLD progression by regulating hepatic steatosis and insulin resistance, suggesting an antagonistic regulatory mechanism underlying NAFLD progression and lipid metabolic dysregulation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted an observational in Non-alcoholic fatty liver disease (NAFLD). Serum LINC00240 was evaluated on Diagnostic value and correlation with lipid metabolism markers. Serum LINC00240 was upregulated in NAFLD patients, positively correlated with lipid metabolism markers, and modulated disease progression by targeting miR-133a-3p.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: